Small K M, Forbes S L, Rahman F F, Bridges K M, Liggett S B
Departments of Medicine and Molecular Genetics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
J Biol Chem. 2000 Jul 28;275(30):23059-64. doi: 10.1074/jbc.M000796200.
The alpha(2)-adrenergic receptors (alpha(2)ARs) play a critical role in modulating neurotransmitter release in the central and peripheral sympathetic nervous systems. A polymorphism of the alpha(2)AR subtype localized to human chromosome 4 (the pharmacologic alpha(2C)AR subtype) within an intracellular domain has been identified in normal individuals. The polymorphism (denoted Del322-325) is because of an in-frame 12-nucleic acid deletion encoding a receptor lacking Gly-Ala-Gly-Pro in the third intracellular loop. To delineate the functional consequences of this structural alteration, Chinese hamster ovary cells were permanently transfected with constructs encoding wild-type human alpha(2C)AR and the polymorphic receptor. The Del322-325 variant had decreased high affinity agonist binding (K(H) = 7.3 +/- 0.95 versus 3.7 +/- 0.43 nm; %R(H) = 31 +/- 4 versus 49 +/- 4) compared with wild-type indicating impaired formation of the agonist-receptor-G protein complex. The polymorphic receptor displayed markedly depressed epinephrine-promoted coupling to G(i), inhibiting adenylyl cyclase by 10 +/- 4.3% compared with 73 +/- 2.4% for wild-type alpha(2C)AR. This also was so for the endogenous ligand norepinephrine and full and partial synthetic agonists. Depressed agonist-promoted coupling to the stimulation of MAP kinase ( approximately 71% impaired) and inositol phosphate production ( approximately 60% impaired) was also found with the polymorphic receptor. The Del322-325 receptor was approximately 10 times more frequent in African-Americans compared with Caucasians (allele frequencies 0.381 versus 0.040). Given this significant loss of function phenotype in several signal transduction cascades and the skewed ethnic prevalence, Del322-325 represents a pharmacoethnogenetic locus and may also be the basis for interindividual variation in cardiovascular or central nervous system pathophysiology.
α₂ - 肾上腺素能受体(α₂ARs)在调节中枢和外周交感神经系统的神经递质释放中起关键作用。在正常个体中已鉴定出定位于人类4号染色体上的α₂AR亚型(药理学上的α₂C AR亚型)在细胞内结构域存在一种多态性。该多态性(记为Del322 - 325)是由于编码的受体在第三个细胞内环中缺少Gly - Ala - Gly - Pro的12个核酸框内缺失。为了阐明这种结构改变的功能后果,用编码野生型人α₂C AR和多态性受体的构建体永久转染中国仓鼠卵巢细胞。与野生型相比,Del322 - 325变体的高亲和力激动剂结合减少(K(H) = 7.3±0.95对3.7±0.43 nM;%R(H) = 31±4对49±4),表明激动剂 - 受体 - G蛋白复合物形成受损。多态性受体显示肾上腺素促进与G(i)偶联明显降低,与野生型α₂C AR的73±2.4%相比,腺苷酸环化酶抑制率为10±4.3%。内源性配体去甲肾上腺素以及完全和部分合成激动剂也是如此。多态性受体还发现激动剂促进与丝裂原活化蛋白激酶刺激的偶联降低(约71%受损)和肌醇磷酸生成降低(约60%受损)。与白种人相比,非洲裔美国人中Del322 - 325受体的频率约高10倍(等位基因频率0.381对0.040)。鉴于在几个信号转导级联中存在这种明显的功能丧失表型以及种族患病率的偏差,Del322 - 325代表一个药物民族遗传学位点,也可能是心血管或中枢神经系统病理生理学个体间差异的基础。